Title: Characteristics of COVID-19 recurrence: a systematic review and meta-analysis

Running title: COVID-19 recurrence: a meta-analysis

Tung Hoang^{1,2}

¹ Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam

² Faculty of Pharmacy, Duy Tan University, Da Nang 550000, Vietnam

Correspondence: Tung Hoang, MPH, BPharm.

1) Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam

2) Faculty of Pharmacy, Duy Tan University, Da Nang 550000, Vietnam

2) Phone: 82-10-9820-7796

3) Email : hoangtungphup@gmail.com; hoangtung@duytan.edu.vn

4) ORCID : <https://orcid.org/0000-0001-6653-3406>

Abstract

Background: Previous studies reported the recurrence of coronavirus disease 2019 (COVID-19) among discharge patients. This study aimed to examine the characteristic of COVID-19 recurrence cases by performing a systematic review and meta-analysis.

Methods: A systematic search was performed in PubMed and Embase and gray literature up to September 17, 2020. A random-effects model was applied to obtain the pooled prevalence of disease recurrence among recovered patients and the prevalence of subjects underlying comorbidity among recurrence cases. The other characteristics were calculated based on the summary data of individual studies.

Results: A total of 41 studies were included in the final analysis, we have described the epidemiological characteristics of COVID-19 recurrence cases. Of 3,644 patients recovering from COVID-19 and being discharged, an estimate of 15% (95% CI, 12% to 19%) patients was re-positive with SARS-CoV-2 during the follow-up. This proportion was 14% (95% CI, 11% to 17%) for China and 31% (95% CI, 26% to 37%) for Korea. Among recurrence cases, it was estimated 39% (95% CI, 31% to 48%) subjects underlying at least one comorbidity. The estimates for times from disease onset to admission, from admission to discharge, and from discharge to RNA positive conversion were 4.8, 16.4, and 10.4 days, respectively.

Conclusion: This study summarized up-to-date evidence from case reports, case series, and observational studies for the characteristic of COVID-19 recurrence cases after discharge. It is recommended to pay attention to follow-up patients after discharge, even if they have been in quarantine.

Keywords: COVID-19; prevalence; recurrence; meta-analysis

Introduction

Since December 2019, the world has been experiencing a public health crisis due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of September 01, 2020, about 26 million confirmed cases and 0.8 million deaths were reported from 213 countries and territories ¹. Several nationwide studies retrospectively investigated clinical features and the epidemiological characteristics of patients infected with SARS-CoV-2 ²⁻⁴. Particularly, aging and underlying chronic diseases were reported to much contribute to the severity of coronavirus disease 2019 (COVID-19) ^{5,6}. However, patients with COVID-19 were generally less severe than SARS and Middle East respiratory syndrome (MERS), with the fatality rate of 9.6%, 34.3%, and 6.6% for SARS, MERS, and COVID-19, respectively ⁷. Recently, it has been reported that SARS-CoV-2 RNA shedding duration could prolong up to 83 days ⁸. In addition, the repositive SARS-CoV-2 RNA test has been observed among patients who had been discharged from health care units and received regular follow-up ⁸. Therefore, this systematic review and meta-analysis was conducted to examine the prevalence of the RNA repositive test for SARS-CoV-2 among recovered patients, the prevalence of subjects underlying comorbidity among recurrence cases, in addition to times from disease onset to hospital admission, from admission to hospital discharge, and from discharge to positive RNA conversion.

Methods

An electronic search of PubMed and Embase was conducted for English language studies published from the inception until September 17, 2020. The keywords for searching were as follows: “(COVID-19 OR SARS-CoV-2) AND (recurrence OR recurrences OR reinfection OR re-infection)”. Additionally, hand searching for related reports of the Centers for Disease Controls and bibliography of relevant studies was performed to obtain relevant information. For each study, the following information was extracted: first author’s name, country, study type, number of recurrence cases and discharged patients, the sample used for reverse transcription polymerase chain reaction (RT-PCR), mean or median age (years), number of males, females, and cases underlying any chronic diseases (including chronic obstructive pulmonary

disease, cardiovascular disease, hypertension, diabetes, liver or kidney disease, and cancer), times from disease onset to admission, from admission to discharge, and from discharge to positive conversion (days). In this study, heterogeneity was quantified by the I^2 statistics, in which $I^2 > 50\%$ was defined as potential heterogeneity⁹. Given data are from different populations of various characteristics, a random-effects model was used to calculate the pooled effect size and its 95% confidence interval (CI) when the evidence from at least two individual studies was available¹⁰. All the statistical analyses were performed using STATA 14.0 software.

Results

The study selection process is presented in **Figure 1**. Initial 550 records were retrieved through PubMed (N=239) and Embase (N=311) and additional 1 gray literature through hand searching was identified. Among records after removing duplicates and non-English publications (N=128), 423 studies were potentially relevant through reviewing titles and abstracts. After reviewing full-text articles, 15 studies were excluded because they reported overlapping cases (N=6) or irrelevant population (N=3), there was no information for outcomes of interest (N=4), and they were studies of mechanisms or modeling (N=2). The remaining 41 studies were therefore eligible for the final analysis¹¹⁻⁵¹.

A detailed description of extracted data of included studies is shown in **Table 1**. Thirty-eight studies reported 466 recurrence cases from China (N=33, 435 cases), Korea (N=1, 83 cases), Iran (N=1, 1 case), Brunei (N=1, 21 cases), Italy (N=2, 3 cases), France (N=1, 11 cases), Brazil (N=1, 1 case), and US (N=1, 1 case). The study design included case reports (N=14), case series (N=6), and observational studies (N=21).

The calculation of the epidemiological characteristics of COVID-19 recurrence cases is presented in **Table 2**. Data for age were provided from 34 studies for 379 recurrence cases, with a mean age of 41.7 years. Among 542 recurrence cases from 39 studies, 233 cases were males, which accounted for 43%. Times from disease onset to admission, from admission to discharge, and from discharge to RNA positive conversion were available for 52, 276, 464 cases from 13, 22, and 31 studies, respectively. The estimates

for times from disease onset to admission, from admission to discharge, and from discharge to RNA positive conversion were 4.8, 16.4, and 10.4 days, respectively.

The prevalence of COVID-19 recurrence cases after discharge was calculated from data of 21 observational studies (**Figure 2**). Among 3,644 discharged patients, the RT-PCR test turned to be positive in 406 Chinese, 83 Korean, and 21 Bruneian subjects. Overall, the prevalence of recurrence cases was 15% (95% CI, 12% to 19%). Substantial heterogeneity among studies was observed, with I^2 of 86.32%. In the subgroup analysis by population, the prevalence was reported to be 14% (95% CI, 11% to 17%) for China, 31% (95% CI, 26% to 37%) for Korea, and 20% (95% CI, 13% to 28%) for Brunei.

Furthermore, it was reported 106 subjects underlying comorbidity among a total of 271 recurrence cases, which accounted for 39% (95% CI, 31% to 48%) (**Figure 3**). There was no evidence of heterogeneity ($I^2=42.08\%$). Subgroup analysis showed the proportion of 64% (95% CI, 35% to 85%) for France cases and 38% (30% to 45%) for Chinese cases.

Discussion

In this systematic review and meta-analysis of 41 studies, we have described the epidemiological characteristics of COVID-19 recurrence cases. Of 3,644 patients recovering from COVID-19 and being discharged, an estimate of 15% (95% CI, 12% to 19%) of patients was repositive with SARS-CoV-2 during the follow-up. This proportion was 14% (95% CI, 11% to 17%) for China, 31% (95% CI, 26% to 37%) for Korea, and 20% (95% CI, 13% to 28%) for Brunei. Among recurrence cases, it was estimated 39% (95% CI, 31% to 48%) subjects underlying at least one comorbidity.

According to the guidelines of the World Health Organization, a patient can be discharged from the hospital after two consecutive negative results in a clinically recovered patient at least 24 hours apart⁵². However, the discharge criteria for confirmed COVID-19 cases are additionally required according to different countries⁵³. The determination of recurrence cases can be caused by false negatives, which ranged from 2% to 29% according to a meta-analysis of 957 hospitalized patients⁵⁴. The reason for false negatives can be due to the source of specimens, sampling procedure, and the sensitivity and specificity of

the test kit⁸. In a preprint study of 213 Chinese patients, a total of 205 throat swabs, 490 nasal swabs, and 142 sputum samples were collected, and the false-negative rates were reported of 40%, 27%, and 11% for the throat, nasal, and sputum samples, respectively⁵⁵. Due to the lack of individual data, we were not able to examine the prevalence of recurrence cases in the subgroup analysis by types of specimens.

Furthermore, it may require considering prolonged SARS-CoV-2 shedding in asymptomatic or mild cases and recurrence of viral shedding⁵⁶. Data from 68 patients revealed a significantly longer duration of viral shedding from sputum specimens (34 days) than nasopharyngeal swabs (19 days)⁵⁷. Consistent findings were reported in an asymptomatic case with viral detection positive in stool but negative in nasopharyngeal swab lasts for 42 days⁵⁸. Similarly, the positive rate of the SARS-CoV-2 RNA test was shown to be highest for the sputum sample (100%), followed by nasal swab (75%), oral swab (40%), and stool specimen (38%)⁵⁹. Nevertheless, although the RT-PCT results of discharge patients were possible to turn positive, it is necessary to distinguish between reactivation and reinfection cases⁸.

Factors related to the recurrence of COVID-19 remain unclear because of inconsistent findings. Although disease severity may be associated with the worse immune response, An J *et al.* reported the lower recurrence rate among subjects with severe or moderate disease at baseline than those with mild disease (odds ratio [OR]=0.23, 95% CI=0.10-0.53)¹². However, the proportion in subjects with severe disease did not differ in those with moderate or mild disease (OR=1.06, 95% CI=0.57-1.96)¹⁷. Also, while subjects underlying diseases such as hypertension and diabetes are more likely to be susceptible with disease infection and severity⁶⁰, the recurrence proportion was not significantly different between comorbidity carriers and noncarriers, in Chen *et al.*'s study (OR=0.71, 95%=0.42-1.20 for hypertension and OR=0.85, 95% CI=0.42-1.75 for diabetes)¹⁷ and Huang *et al.*'s study (OR=0.98, 95%=0.52-1.87 for hypertension and OR=0.46, 95% CI=0.14-1.55 for diabetes)²⁵.

This study summarized up-to-date evidence from case reports, case series, and observational studies for the characteristic of COVID-19 recurrence cases after discharge. However, several limitations need to be mentioned. First, 80% of the included studies (33/41) with 78% recurrence cases (435/556) come from the Chinese population, which may reduce the availability to generalize the pooled estimates into other

populations. Second, heterogeneity for the prevalence of recurrence cases was substantially presented among studies. The different characteristics, discharge criteria, and the test samples used among study populations included in this meta-analysis may have contributed to the heterogeneity. Last, all the estimates in the current study are based on aggregate data from published articles. Failure to obtain individual patient data may lead to bias due to the lack of full exploration and adjustment for patient characteristics⁶¹.

In summary, an estimate of 15% of COVID-19 patients was repositive after discharge. Among them, 39% of subjects were underlying comorbidity. It is recommended to pay attention to follow-up patients after discharge by closely monitoring their RT-PCR results, even if they have been in quarantine for 14 days. Further studies are needed to determine factors associated with positive RT-PCR in COVID-19 patients after discharge.

Disclosure: The author has no potential conflicts of interest.

Funding: This study receives no funding.

Data availability statement: Data for all the analyses are available in Table 1.

Author's contributions: TH designed the outline of the work, analyzed the data, and wrote the **ORCID:**

Tung Hoang: 0000-0001-6653-3406

Reference

1. Worldometer. COVID-19 coronavirus pandemic. <https://www.worldometers.info/coronavirus/>. Accessed September 01, 2020.
2. Sung HK, Kim JY, Heo J, Seo H, Jang YS, Kim H, et al. Clinical course and outcomes of 3,060 patients with coronavirus disease 2019 in Korea, January-May 2020. *J Korean Med Sci* 2020;35(30):e280.
3. Yoneoka D, Kawashima T, Tanoue Y, Nomura S, Ejima K, Shi S, et al. Early SNS-based monitoring system for the COVID-19 outbreak in Japan: a population-level observational study. *J Epidemiol* 2020;30(8):362-70.
4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382(18):1708-20.
5. Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. *Diabetes Metab Syndr* 2020;14(5):1017-25.
6. Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. *Infect Chemother* 2020;52(2):154-64.
7. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. *J Hum Genet* 2020.
8. Hoang VT, Dao TL, Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. *J Med Virol* 2020.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60.
10. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials* 2007;28(2):105-14.

11. Alonso FOM, Sabino BD, Guimarães M, Varela RB. Recurrence of SARS-CoV-2 infection with a more severe case after mild COVID-19, reversion of RT-qPCR for positive and late antibody response: Case report. *J Med Virol* 2020.
12. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. *medRxiv* 2020.
13. Batisse D, Benech N, Botelho-Nevers E, Bouillier K, Collarino R, Conrad A, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? *J Infect* 2020.
14. Bongiovanni M, Basile F. Re-infection by COVID-19: a real threat for the future management of pandemic? *Infect Dis (Lond)* 2020;52(8):581-2.
15. Cao H, Ruan L, Liu J, Liao W. The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge. *J Med Virol* 2020.
16. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. *Int J Infect Dis* 2020;93:297-9.
17. Chen J, Xu X, Hu J, Chen Q, Xu F, Liang H, et al. Clinical course and risk factors for recurrence of positive SARS-CoV-2 RNA: a retrospective cohort study from Wuhan, China. *MedRxiv* 2020.
18. Chen Y, Bai W, Liu B, Huang J, Laurent I, Chen F, et al. Re-evaluation of retested nucleic acid-positive cases in recovered COVID-19 patients: Report from a designated transfer hospital in Chongqing, China. *J Infect Public Health* 2020;13(7):932-4.
19. Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. A case report of possible novel coronavirus 2019 reinfection. *Am J Emerg Med* 2020.
20. Fu W, Chen Q, Wang T. Letter to the Editor: three cases of redetectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies. *J Med Virol* 2020.
21. Gao G, Zhu Z, Fan L, Ye S, Huang Z, Shi Q, et al. Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case. *Infection* 2020:1-5.

22. Geling T, Huaizheng G, Ying C, Hua H. Recurrent positive nucleic acid detection in a recovered COVID-19 patient: A case report and literature review. *Respir Med Case Rep* 2020;31:101152.
23. He F, Luo Q, Lei M, Fan L, Shao X, Hu K, et al. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. *Clin Rheumatol* 2020;39(9):2803-10.
24. Hu R, Jiang Z, Gao H, Huang D, Jiang D, Chen F, et al. Recurrent Positive Reverse Transcriptase-Polymerase Chain Reaction Results for Coronavirus Disease 2019 in Patients Discharged From a Hospital in China. *JAMA Netw Open* 2020;3(5):e2010475.
25. Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, et al. Recurrence of SARS-CoV-2 PCR positivity in COVID-19 patients: a single center experience and potential implications. *medRxiv* 2020.
26. Korea Centers for Disease Control & Prevention. Findings from investigation and analysis of re-positive cases (19 May 2020). https://www.cdc.go.kr/board/board.es?mid=&bid=0030&act=view&list_no=367267&nPage=1. Accessed August 17, 2020.
27. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol* 2020.
28. Li XJ, Zhang ZW, Zong ZY. A case of a readmitted patient who recovered from COVID-19 in Chengdu, China. *Critical Care* 2020;24(1).
29. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-Cov-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu, China. *J Med Virol* 2020.
30. Liang C, Cao J, Liu Z, Ge F, Cang J, Miao C, et al. Positive RT-PCR test results after consecutively negative results in patients with COVID-19. *Infect Dis (Lond)* 2020;52(7):517-9.
31. Liu T, Wu S, Zeng G, Zhou F, Li Y, Guo F, et al. Recurrent positive SARS-CoV-2: Immune certificate may not be valid. *J Med Virol* 2020.

32. Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al. Recurrence of COVID-19 after recovery: a case report from Italy. *Infection* 2020;1-3.
33. Luo A. Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital discharge: A case report. *Journal of Traditional Chinese Medical Sciences* 2020.
34. Mardani M, Nadji SA, Sarhangipor KA, Sharifi-Razavi A, Baziboroun M. COVID-19 infection recurrence presenting with meningoencephalitis. *New Microbes New Infect* 2020;37:100732.
35. Peng J, Wang M, Zhang G, Lu E. Seven discharged patients turning positive again for SARS-CoV-2 on quantitative RT-PCR. *Am J Infect Control* 2020;48(6):725-6.
36. Qiao XM, Xu XF, Zi H, Liu GX, Li BH, Du X, et al. Re-positive Cases of Nucleic Acid Tests in Discharged Patients With COVID-19: A Follow-Up Study. *Front Med (Lausanne)* 2020;7:349.
37. Qu YM, Kang EM, Cong HY. Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19. *Travel Med Infect Dis* 2020;34:101619.
38. Tian M, Long Y, Hong Y, Zhang X, Zha Y. The treatment and follow-up of 'recurrence' with discharged COVID-19 patients: data from Guizhou, China. *Environ Microbiol* 2020;22(8):3588-92.
39. Wang P. Recurrent presence of SARS-CoV-2 RNA in a 33-year-old man. *J Med Virol* 2020.
40. Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, et al. The Clinical Features and Outcomes of Discharged Coronavirus Disease 2019 Patients : A Prospective Cohort Study. *Qjm* 2020.
41. Wong J, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam. *J Med Virol* 2020.
42. Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. *J Med Virol* 2020.

43. Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. *Euro Surveill* 2020;25(10).
44. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J Infect* 2020;80(5):e14-e7.
45. Yuan B, Liu HQ, Yang ZR, Chen YX, Liu ZY, Zhang K, et al. Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. *Sci Rep* 2020;10(1):11887.
46. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. PCR Assays Turned Positive in 25 Discharged COVID-19 Patients. *Clin Infect Dis* 2020.
47. Zhang B, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, et al. Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19). *J Infect* 2020;81(2):e49-e52.
48. Zheng KI, Wang XB, Jin XH, Liu WY, Gao F, Chen YP, et al. A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. *J Gen Intern Med* 2020;35(7):2205-6.
49. Zhou X, Zhou J, Zhao J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. *BMC Infect Dis* 2020;20(1):500.
50. Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection. *J Clin Lab Anal* 2020;34(7):e23392.
51. Zou Y, Wang BR, Sun L, Xu S, Kong YG, Shen LJ, et al. The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: investigation of patients from multiple medical institutions in Wuhan, China. *J Infect Dis* 2020.
52. Nebahay S. WHO is investigating reports of recovered COVID patients testing positive again. <https://www.reuters.com/article/us-health-coronavirus-who/who-is-investigating-reports-of-recovered-covid-patients-testing-positive-again->

- [idUSKCN21T0F1#:~:text=According%20to%20the%20WHO's%20guidelines,24%20hours%20a part%2C%20it%20added](#). Accessed September 01, 2020.
53. European Centers for Disease Prevention and Control. Discharge criteria for confirmed COVID-19 cases - When is it safe to discharge COVID-19 cases from the hospital or end home isolation? <https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Discharge-criteria.pdf>. Accessed September 01, 2020.
 54. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. *medRxiv* 2020.
 55. Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection - challenges and implications. *N Engl J Med* 2020;383(6):e38.
 56. Miyamae Y, Hayashi T, Yonezawa H, Fujihara J, Matsumoto Y, Ito T, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. *Int J Infect Dis* 2020;97:293-5.
 57. Wang K, Zhang X, Sun J, Ye J, Wang F, Hua J, et al. Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019. *Chest* 2020.
 58. Jiang X, Luo M, Zou Z, Wang X, Chen C, Qiu J. Asymptomatic SARS-CoV-2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days. *J Med Virol* 2020.
 59. Yan-Xin C, Ming-Lin X, Xiao-Hui F, Lei Y, Xu-Ying W, Qian Z, et al. Analysis of false negative results in throat swab nucleic acid test of severe acute respiratory syndrome coronavirus 2. *Academic Journal of Second Military Medical University* 2020;41(6):592-5.
 60. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. *J Korean Med Sci* 2020;35(25):e237.

61. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data.
BMC Med Res Methodol 2005;5:14.

Table 1. Summary of studies reporting recurrence of COVID-19 cases after discharge

Study	Country	Study type	No. of recurrence cases	No. of discharged patients	Sample for testing	Age (years)	Male/female	No. of cases underlying comorbidity	Times from onset to admission (days)	Times from admission to discharge (days)	Times from discharge to positive conversion (days)
Alonso FOM	Brazil	Case report	1		Respiratory swab	26	1/0				34
An J	China	Observational	38	242	Nasal and anal swab	32.8	16/22				
Batisse D	France	Case series	11		Naso-pharyngeal swabs	55	6/5	7			
Bongiovanni M	Italy	Case series	2		Nasopharyngeal swab		0/2	2			
Cao H	China	Observational	8	108	Deep nasal cavity or throat swab	54.4	3/5	0			16.3
Chen D	China	Case report	1		Oropharyngeal swab	46	1/0		8		
Chen J	China	Observational	81	1087	Throat swab	62	30/51	29		12	9
Chen Y	China	Observational	4	17	Oropharyngeal, nasopharyngeal, and anal swab	32	2/2			18.25	11.25
Duggan NM	US	Case report	1			82	1/0	1	7	39	10
Fu W	China	Case series	3		Nasopharyngeal swab	48	1/2			12	9.3
Gao G	China	Case report	1			70	1/0	1	5	15	12
Geling T	China	Case report	1		Pharyngeal swab	24	1/0	0		10	8
He F	China	Case report	1		Throat swab	39	0/1		10	13	8
Hu R	China	Observational	11	69	Nasopharyngeal swab	27	7/4	3		10	14
Huang J	China	Observational	69	414	Nasopharyngeal and anal swab		28/41	22	3	20	11
KCDC	Korea	Observational	83	269			28/41				14.3
Li J	China	Case report	1		Nasopharyngeal and oropharyngeal samples	71	0/1		14		
Li XJ	China	Case report	1			41	1/0		19	9	19
Li Y	China	Observational	6	13	Oral swabs, nasal swabs, sputum, blood, faeces,	51.3	3/3	3			10.2

Study	Country	Study type	No. of recurrence cases	No. of discharged patients	Sample for testing	Age (years)	Male/female	No. of cases underlying comorbidity	Times from onset to admission (days)	Times from admission to discharge (days)	Times from discharge to positive conversion (days)
					urine, vaginal secretions, and milk						
Liang C	China	Observational	11	22	Throat swab						
Liu T	China	Observational	11	150	Throat swab	49	6/5				
Loconsole D	Italy	Case report	1		Nasopharyngeal swab	48	1/0	0		15	30
Luo A	China	Case report	1		Throat swab	58	0/1		7	15	22
Mardani M	Iran	Case report	1		Nasopharyngeal swab	64	0/1				
Peng J	China	Case series	7		Throat swab		4/3			16.7	10.1
Qiao XM	China	Observational	1	15	Nasopharyngeal and throat swab	30	0/1			14	15
Qu YM	China	Case report	1		Throat swab and sputum	49	1/0		4		
Tian M	China	Observational	20	147	Pharyngeal swabs	37.15	11/9	7	2.5	18.65	17.25
Wang P	China	Case report	1		Throat swab	33	1/0		8	21	15
Wang X	China	Observational	8	131		48.75	4/4	0			11.375
Wong J	Brunei	Observational	21	106	Nasopharyngeal swab	43.1	12/9			17	13
Xiao AT	China	Observational	15	70	Throat swab, deep nasal cavity swab	64	9/6				
Xing Y	China	Case series	2		Throat swab and stool tests		1/1		6	15.5	6.5
Ye G	China	Observational	5	55	Throat swab	32.4	2/3	0			10.6
Yuan B	China	Observational	20	182	Nasopharyngeal swab or anal swab	39.9	7/13	6	5.1	20.8	9.45
Yuan J	China	Observational	25	172	Cloacal swab and nasopharyngeal swab	28	8/17			15.36	5.23
Zhang B	China	Case series	7		Throat and rectal swab	22.4	6/1			15.4	9.7
Zheng KI	China	Observational	3	20	Salivary and fecal						7
Zhou X	China	Case report	1		Oropharyngeal swab	40	1/0		6	16	7

Study	Country	Study type	No. of recurrence cases	No. of discharged patients	Sample for testing	Age (years)	Male/ female	No. of cases underlying comorbidity	Times from onset to admission (days)	Times from admission to discharge (days)	Times from discharge to positive conversion (days)
Zhu H	China	Observational	17	98	Sputum and pharyngeal swab	54	5/12				4
Zou Y	China	Observational	53	257	Throat swabs	62.19	23/30	29			4.6

Table 2. Epidemiological characteristics of COVID-19 recurrence cases

Characteristic	No. studies	No. of recurrence cases	Result
Age (years)	34	379	41.7
Male (no., %)	39	233	542 (43%)
Times from onset to admission (days)	13	52	4.8
Times from admission to discharge (days)	22	276	16.4
Times from discharge to positive conversion (days)	31	464	10.4

Figure 1. Flowchart of study selection

Figure 2. Forest plot for meta-analysis of COVID-19 recurrence prevalence

Figure 3. Forest plot for meta-analysis of comorbidity among COVID-19 recurrence cases